----item----
version: 1
id: {0F8A58EA-D3DE-4EB3-B830-CC103874F46D}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/30/Allergan Uses Its Cash For Kythera
parent: {33D065F8-4841-41E4-809A-5D1E27443795}
name: Allergan Uses Its Cash For Kythera
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: fc87b4e0-da45-44ff-8935-5768a33dc534

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 194

{1D288E18-BAFF-4498-B284-EF9BC8D32E30}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{8B2376D2-D914-41D6-9402-D3CD38CABF23}|{3C238C65-DA89-47D4-9955-405FAAE164E0}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 34

Allergan Uses Its Cash For Kythera
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 34

Allergan Uses Its Cash For Kythera
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1284

<p><p>Now that it's flush with cash, Allergan has opted to change the terms of its acquisition for Kythera Biopharmaceuticals. The pair announced Aug. 5 that Allergan will now pay $75 per share for Kythera in all cash. </p><p>The deal was originally announced on June 17 when Allergan said it would buy the aesthetic drug maker for $75 per share <a href="http://#http://www.scripintelligence.com/home/Allergan-buys-chin-fat-firm-Kythera-for-2.1bn-358996" target="_new">in a deal</a> that was 80% cash and 20% equity. </p><p>Allergan bought Kythera for its submental fat drug, which treats the condition more commonly known as a double chin. Allergan, previously known as Actavis, is rounding out the aesthetics business the company created with its blockbuster wrinkle reducer <i>Botox</i> (onabotulinumtoxinA).</p><p>Allergan has a bit more cash in the bank now that it sold its generics business to Teva Pharmaceuticals in late July. The $40.5bn sale resulted in <a href="http://#http://www.scripintelligence.com/home/With-36bn-from-Teva-what-should-Allergan-buy-next-359644" target="_new">$36bn in after-tax proceeds</a> to fatten Allergan's coffers. </p><p>The company said it would use the proceeds to pay down debt from previous transactions, as well as fund new M&A. </p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 34

Allergan Uses Its Cash For Kythera
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150730T202312
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150730T202312
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150730T202312
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029436
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 34

Allergan Uses Its Cash For Kythera
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198800586
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{2D771726-4AE8-4124-B380-232612225CB7}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359704
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042432Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

fc87b4e0-da45-44ff-8935-5768a33dc534
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042432Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
